I. Introduction
It has been documented that breast cancer is a heterogeneous disease with variable biological and clinical characteristics because of its different genetic make-up .It is well known that Proto-oncogenes and tumor suppressor genes are two classes of genes, that play a central role in the regulation of cell growth and differentiation. So any alterations in one or more of these genes appear to play an important role in the pathogenesis of most human malignancies. HER-2/neu proto-oncogene amplification and or over expression is one of the most important alterations encountered in breast cancer. HER-2/neu proto-oncogene (also called cerbB2) is located on chromosome 17q11, which encodes for p185 a transmembrane glycoprotein with tyrosine kinase -Activity that belongs to the family of epidermal growth factor receptors. HER2/neu proto-oncogene is amplified and or over expressed in approximately in 25-30% of invasive primary breast cancers.An association have been found to exist between amplification and or over expression of HER-2/neu and a wide variety of different clinical and pathological features of breast carcinoma that include: Large tumor size, high grade, lack of steroid receptor expression, axillary lymph nodes metastasis, advanced stage, early relapse, and reduced overall survival. From a clinical point of view HER-2/neu receptor has become important as a target for antibody-based therapy with trastuzumab (Herceptin). The interesting point of such a specific treatment is that only patients with tumors that over express HER-2/neu benefit from such a therapy. For that reason, the determination of HER-2/neu status in breast cancer is becoming of great interest, and recently this treatment has been shown to improve patient's outcome markedly.
Therefore, we plan to study this important genetic marker i.e. ER, PR, Her-2/Neu which could be used as a prognostic factor for the early management of this malignancy.This could hopefully help the clinicians better understand the disease manifestation in our patients, and, accordingly, help them develop a platform on which further disease investigation and clinical management strategies could be based.
II.
Aims & Objectives 2.1 To Study ER, PR & Her-2/neu reactivity in the patient of breast cancer.
2.2 To determine the proportion of HER-2/ neu receptor positivity in patients of carcinoma breast. 
III. Material and Methods

Study design:
IV.
Observation and Discussion
The association between Her-2 gene amplification and poor prognosis was first determined in 1987 by Slamonet al. [1] In our study of 203 patients of breast cancer, 58.1% (n=118) patients were >45years, while 41.9% (n=85) were ≤ 45 years of age with mean age of 48.4 years. Nidal M Almsari et al [2] had mean age of 47 years in their study with 37% patients within the age of 45 years. So now looking to the above ratio this is clear that more younger patients are coming with cancer breast in India. In our study 37.4% (n= 76) patients, had ER positive status and 62.6% (n=127) patients had ER negative status while 34% (n= 69) patients had PR positive status and 66% (n=134) patients had PR negative In this study, we found that 71 (35 %) out of 203 cases were HER-2/neu positive & 132 (65%) cases were Her-2/neu negative. Although there is a wide variation (15-35%) in HER-2/neu over-expression and amplification, our figureappears to be higher side of commonly accepted rate of 15 to 35% may be because of we were getting more patients of younger age group.Nidal M Almasari(2)had 25% Her-2/neu positive & 75% Her-2/neu negative patients in their study.
Profile of patients of breast carcinoma (N
Association of Her-2/Neu receptor status with age
Her-2/neu protein over-expression was present in 31 out of 85 (36.5%) patients with age ≤45 years and in 40 out of 118 (33.9%) patients with age of > 45 years. (Chi-square = .144 with 1 degree of freedom ; p = .704) Franco Rilke [3] found that HER-2/neu over-expression is associated with young age; we also have high ratio of Her-2/neu over expression in young patients Most of the patients in our study who had Her-2/neu protein over-expression were ER-/PR-. This group appeared to represent an aggressive form of breast cancer, presenting at a younger age with large tumor size. Despite the great variation in levels of HER-2/neu positivity, nearly all investigators report a negative relationship between HER-2/neu status and steroid receptors levels [6, 7, 8, 9] This inverse association has been linked to the fact that estrogens and its receptor are required to suppress HER-2. This leads to lower or absent hormone receptors in women with HER-2/neu positive breast cancers. This is one of the reasons why women who express HER-2/neumay be resistant to tamoxifen [10] . In summary, in the study of 203 cases of breast carcinoma in which Her-2/neu protein receptor over-expression by IHC was performed, a statistically significant association was established between Her-2/neu protein receptor over-expression and large tumor size ( p value <.05), which were further increased when tumor size was more than 5 cms in size, tumor grade (p value > .05), infiltrative ductal carcinoma and comedo carcinoma subtypes (p value <.05). Most of the patients in our study who had Her-2/neu protein over-expression were ER-/PR-but we did not get statistically significant value because significant number of patients had triple negative (ER-,/PR-/Her-2/neu -ve) disease. Her-2/neu protein receptor positivity was not significantly associated with age (p value >.05), menopausal status (p value >.05), number of lymph node.
V. Conclusion
HER-2/neu status in breast cancer is important because it provides valuable prognostic, predictive, and therapeutic information. The association of HER-2/neu with additional prognostic factors has always been of interest.
Her-2/neu over-expression tumor was shown to increase disease recurrence and metastasis and thus shorter survival. As over-expression of Her-2/neu protein and amplification of Her-2/neu gene is also associated with poor prognostic tumor characteristics such as high histological grade, high proliferative index, negative or lower estrogen receptor (ER) expression, lymphoid infiltration, p53 mutation, absence of bcl-2, and absence of lobular histology. Her-2/neu +ve and ER-/PR-ve group appeared to represent an aggressive form of breast cancer, presenting at a younger age with large tumor size. We also found a significantly higher rate of HER-2/neu protein over-expression in patients with poor prognostic factor like large size tumor, high grade tumor and lymph node metastasis. We also found more Her-2/neu overexpression in patients with common histopathological tumor like invasive ductal carcinoma (IDC). So, the final conclusion is that Her-2/neu testing along with ER/PR status should be performed routinely in all the patients with newly diagnoses breast cancer. Therapy against Her-2/neu (Traztuzumab) a humanized monoclonal antibody, should be considered to all patients whose tumor are strongly positive for Her-2/neu protein receptor because these patients have poor prognostic factors, higher tumor grade, larger size and carry poor prognosis and there is significant benefit in disease free survival and overall survival with concurrent trastuzumab administered over one year, as reported by Piccart et al [11] 
